Oxaliplatin, folinic acid and 5-fluorouracil (folfox) in pretreated patients with metastatic advanced cancer. The GERCOD (Q34746001)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9500010%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

title

Oxaliplatin, folinic acid and 5-fluorouracil (folfox) in pretreated patients with metastatic advanced cancer. The GERCOD (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9500010%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

1 reference

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9500010%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

A de Gramont

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9500010%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

C Tournigand

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9500010%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

C Louvet

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9500010%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

J L Molitor

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9500010%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

E Raymond

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9500010%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

S Moreau

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9500010%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

J Vignoud

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9500010%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

N Le Bail

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9500010%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

M Krulik

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9500010%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

language of work or name

French

0 references

publication date

1 January 1997

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9500010%20AND%20SRC:MED&resulttype=core&format=json

Revue de Médecine Interne

10 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9500010%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9500010%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9500010%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

page(s)

769-775

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9500010%20AND%20SRC:MED&resulttype=core&format=json

Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial

10 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2897%2989966-3

7 January 2021

A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2897%2989966-3

7 January 2021

Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2897%2989966-3

7 January 2021

Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2897%2989966-3

7 January 2021

Activity of continuous-infusion 5-fluorouracil in patients with advanced colorectal cancer clinically resistant to bolus 5-fluorouracil.

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2897%2989966-3

7 January 2021

Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2897%2989966-3

7 January 2021

A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2897%2989966-3

7 January 2021

Bimonthly high dose leucovorin and 5-fluorouracil 48-hour continuous infusion in patients with advanced colorectal carcinoma. Groupe d'Etude et de Recherche sur les Cancers de l'Ovaire et Digestifs (GERCOD)

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2897%2989966-3

7 January 2021

Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2897%2989966-3

7 January 2021

Phase I study of oxaliplatin in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2897%2989966-3

7 January 2021

Oxalato-platinum or 1-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2897%2989966-3

7 January 2021

Synergistic action of high-dose hydroxyurea when used with cyglophosphamide and certain new organoplatinum complexes in treatment of advanced L1210 leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2897%2989966-3

7 January 2021

Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2897%2989966-3

7 January 2021

10.1016/S0248-8663(97)89966-3

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9500010%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9500010%20AND%20SRC:MED&resulttype=core&format=json